Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) (NQF 0083)

eMeasure Name Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) eMeasure Id 9D20BE15-5A08-48D6-99AF-3170B899FD4A
Version number 1 eMeasure Set Id EA5FE606-9153-4C52-89C8-8CEC97625EF8
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward American Medical Association - Physician Consortium for Performance Improvement
Endorsed by National Quality Forum
Description Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy
Copyright
© 2010 American Medical Association. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
Beta-blockers are recommended for all patients with symptoms of heart failure and left ventricular systolic dysfunction, unless contraindicated. Treatment with beta-blockers has been shown to provide multiple benefits to the patient, including reducing the symptoms of heart failure, improving the clinical status of patients, and decreasing the risk of mortality and hospitalizations.
Clinical Recommendation Statement
Beta-blockers (using 1 of the 3 proven to reduce mortality, i.e., bisoprolol, carvedilol, and sustained release metoprolol succinate) are recommended for all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. (Class I Recommendation, Level of Evidence: A) (ACC/AHA)
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
Reference
Jessup M, Abraham WT, Mancini DM, et al.  DRAFT 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults:  a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines developed in Collaboration With the American Academy of Family Physicians, American College of Chest Physicians, Heart Failure Society of America, and International Society for Heart and Lung Transplantation (Writing Group to Review new evidence and update the 2005 guideline for the management of patients with chronic heart failure) developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung.
Definition
Initial Patient Population(s): Patient Age: Patients aged 18 years and older at the beginning of the measurement period.
			
Diagnosis, Active: Patient has a documented diagnosis of heart failure and who also have Left Ventricular Systolic Dysfunction (LVSD).

Encounter: At least 2 visits with the physician, physician's assistant, or nurse practitioner during the measurement period.
Definition
Denominator(s): All patients aged 18 years and older with a diagnosis of heart failure with left ventricular ejection fraction (LVEF) < 40% or with moderately or severely depressed left ventricular systolic function
Definition
Denominator Exclusion(s): N/A
Definition
Numerator(s): Patients who were prescribed beta-blocker therapy.
Definition
Denominator Exception(s): Documentation of medical reason(s) for not prescribing beta blocker therapy (e.g., clinical contraindication, drug allergy, drug interaction, drug intolerance, other medical reason(s)).

Documentation of patient reason(s) for not prescribing beta blocker therapy (e.g., patient declined).

Documentation of system reason(s) for not prescribing beta blocker therapy.
Guidance
Supplemental Data Elements
Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)".

Table of Contents


Population criteria

Data criteria (QDM Data Elements)

Supplemental Data Elements




Measure set CLINICAL QUALITY MEASURE SET 2011-2012